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Background: We have recently identified HOP hoemobox (HOPX) as a tumor suppressor gene candidate,
characterized by tumor-specific promoter DNA hypermethylation in human cancers, and it can remarkably inhibit
tumors’ aggressive phenotypes. In this current study, we for the first time examined methylation level of HOPX and
tested the functional relevance in pancreatic cancer (PC).
Methods: Clinical features of HOPX promoter hypermethylation was investigated in 89 PC tissues, and
immunohistochemistry was added. We also examined its functional relevance in phenotype assays such as soft
agar, proliferation, invasion, and cell cycle analysis.
Results: PC tissues had HOPX gene hypermethylation as compared to the corresponding normal pancreas tissues,
and its uniqueness was robust to discriminate tumor from normal tissues (AUC= 0.85, P < 0.0001). Unexpectedly,
HOPX was increased in expression in tumor tissues, and immunohistochemistry revealed its predominant
expression in the Langerhans islet cells, where HOPX was reduced in expression for PC cells with promoter
hypermethylation. HOPX transfectants exhibited G1 arrest with subG1 accumulation, and inhibited tumor forming
and invasive ability.
Conclusion: Defective expression of HOPX which is consistent with promoter DNA hypermethylation may explain
aggressive phenotype of pancreatic cancer, and intense expression of HOPX in the Langerhans cells may in turn
uniquely contribute to pancreatic carcinogenesis.
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Global hypomethylation is often accompanied by dense
hypermethylation of the specific promoters in human
cancers [1-3]. Promoter hypermethylation results in gene
silencing, and such genes have proved to have potent
tumor suppressive function and is rather rare [1,4]. We
previously developed pharmacologic reversal of epigen-
etic silencing and uncovered a myriad of transcription-
ally repressed genes in human cancers [5,6]. Using this* Correspondence: komulu@hotmail.co.jp; gekaw@med.kitasato-u.ac.jp
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reproduction in any medium, provided the ortechnique, we have identified several unknown tumor
suppressor gene candidates, which included HOP
homeobox (HOPX) [7,8].
HOPX gene (GeneBank accession number NT
022853), also known as HOP, NECC1, LAGY or OB1,
was initially identified as a gene essential for cardiac
growth and development [9]. Three spliced transcript
variants, HOPX-α, -β, and -γ, encode the same protein,
which contains a putative homeodomain motif that acts
as an adapter protein to mediate transcription [10].
HOPX expression is ubiquitous in wide arrays of normal
tissue, but not in malignant tissues including choriocar-
cinoma, lung, uterine endometrial, and gastrointestinalLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tually involves promoter methylation in esophageal,
endometrial, and gastric cancer [7,8,15]. Also, enforced
HOPX expression inhibited tumor growth and RNA
interference knockdown of endogenous HOPX restored
it [7,8,15]. These findings suggest that the HOPX gene
acts as a tumor suppressor gene.
In this study, we for the first time studied methylation
level of HOPX gene in PC and added the functional
assay to answer the question whether HOPX plays an
important role in pancreatic carcinogenesis.
Methods
Cell lines and tissue samples
The pancreatic cancer cell lines, PK-8, KLM-1, and
NOR-P1 were kindly provided from the Cell Resource
Centre for Biomedical Research Institute of Develop-
ment, Aging and Cancer, Tohoku University (Sendai,
Japan). Six other cell lines, PK-59, PK-45 H, PK-45P,
MIA Paca2, PANC-1, or the esophageal squamous cell
carcinoma (ESCC) cell line TE15 [16] and gastric cancer
cell line KatoIII were purchased from RIKEN BioRe-
source Centre (Ibaraki, Japan). All cell lines except MIA
Paca2 were maintained in RPMI 1640 Medium (GIBCO,
Carlsbad, CA) and MIA Paca2 was maintained in
DMEM (GIBCO), containing 10% fetal bovine serum.
Clinical tissue samples were categorized according to
TNM classification, 7th edition of the Union Internation-
ale Contre Le Cancer (UICC) and the 6th edition of the
Japan Pancreas Society (JPS). The patients’ characteris-
tics were depicted in Additional file 1 Table S1. All tis-
sue samples were collected at the Kitasato University
Hospital, and informed consent was obtained. The
present study was approved by the Ethics Committee of
the Kitasato University.
Bisulfite treatment of DNA and sequencing analysis
Genomic DNA from homogenized bulky tissues and cell
lines was extracted using QIAamp DNA Mini Kit (QIA-
GEN Sciences, Hilden). Bisulfite treatment was done by
using an EpiTect bisulfite kit (QIAGEN) and the DNA was
applied to polymerase chain reaction (PCR). PCR primer
sequences were designed using DNA sequences converted
by bisulfited treatment (Table 1). The PCR products were
sequenced using a Big DyeW Terminator v3.1 Cycle Se-
quencing Kit (Applied Biosystems, Foster City, CA). For the
clonsed sequence analysis, the PCR products were inserted
into pCR4-TOPO vector using a TOPO TA cloning kit for
sequencing (Invitrogen, Carlsbad, CA, USA), selected 15
clones for each sample and then sequenced.
Quantitative-methylation-specific PCR (Q-MSP)
TaqMan methylation specific PCR (Q-MSP) was carried
out using iQ Supermix (Bio-Rad) in triplicate on theiCycler iQTM Real-Time PCR Detection system (Bio-
Rad). PCR conditions and the primer sequences are pro-
vided in Table 1. Serial dilutions of bisulfite modified
DNA from KatoIII were used as positive control and
TE15 as negative control, respectively. The methylation
value was defined by a ratio of HOPX-β divided by β-
actin and then multiplied by 100, according to the com-
parative cycle threshold (CT) method [17].
RNA purification and reverse transcriptase-polymerase
chain reaction
Total RNA from homogenized bulky tissues and cell
lines was extracted using RNeasy Mini Kit (QIAGEN),
and reverse-transcribed with a SuperScript III Reverse
Transcriptase kit (Invitrogen). Quantitative real time
RT-PCR (Q-RT-PCR) for HOPX-β or HOPX-core was
performed using iQTM SYBR Green Supermix (Bio-Rad)
in triplicate on the iCycler iQTM Real-Time PCR Detec-
tion system (Bio-Rad), either (Table 1). Relative quantita-
tive analysis adjusted for β-actin was performed
according to the CT method [17]. Table 1 depicts
sequences of primers/probes and PCR condition.
Immunoprecipitation and Western blotting
Whole cells lysates were obtained using RIPA buffer
(Pierce, Rockford, IL) supplemented with 10 μL/ ml
HaltTM Protease Inhibitor Cocktail Kit (Pierce) and
HaltTM Phosphatase Inhibitor Cocktail Kit (Pierce).
Immunoprecipitation (IP) was performed using Dyna-
beads Protein G (Dynal Biotech, Oslo, Norway), 1 μg of
anti-HOPX mouse IgG1K monoclonal antibody (3D6,
Sigma), and 400 μg of each cell lysates. The anti-HOPX
mouse IgG1K monoclonal antibody (3D6, dilution of
1:1000, Sigma), anti-HOPX rabbit IgG polyclonal anti-
body (FL-73, dilution of 1:200, Santa Cruz Biothecnol-
ogy, Santa Cruz, CA, USA), anti-V5 mouse IgG2a
monoclonal antibody (dilution of 1:5000, Invitrogen),
and anti-β-actin mouse IgG2a monoclonal antibody (di-
lution of 1:10000, Sigma) were used for Western blotting
(WB) or IP/WB.
5-Aza-dC and TSA treatment
Cells (1×106 cells/T-75 flask) were treated with 1 or
5 μM of the demethylating agent 5-aza-20-deoxycytidine
(5-Aza-dC) (Sigma-Aldrich) dissolved in 50% acetic acid
or mock-treatment with PBS including the same amount
of acetic acid every 24 hrs for 4 days. When combined
with the histone deacetylase inhibitor trichostatin A
(TSA) (Sigma-Aldrich), 300 nM TSA was added to the
medium for the final 24 hrs.
Immunohistochemistry
Formalin fixed, paraffin-embedded histological sections
(3 μm thick) were immunostained using the HOPX
Table 1 PCR production and sequence of primers and fluorescent probe
Method Gene Forward primer (50>30) Fluorescent (5030) Reverse primer (50>30)
bisulfite sequencing† HOPX-β TAGTITTGTTTGGAAGAGGGGCG AACCTCCCCTAAAAACAAACTTAAC
Q-MSP{ HOPX-β TTTGGAGAGGGTTTTAAAGCG FAM-CGGAGATAGAAGGTCGTTTATCGGGGAGGTCG-TAMRA AACAAACTTAACAAATCGCGAA
Q-MSP{ β-actin TGGTGATGGAGGAGGTTTAGTAAGT FAM-ACCACCACCCAACACACAATAACAAACACA-TAMRA AACCAATAAAACCTACTCCTCCCTTAA
RT-PCR} HOPX-α and γ CAAACCCAGGGCTTGCGCTT GCGGAGGAGCGAAACAGAGAT
RT-PCR}/Q-RT-PCR HOPX-β GGTCCCCCTTTCGGGAGGAA GCGGAGGAGAGAAACAGAGAT
RT-PCR}/Q-RT-PCR HOPX-core CAGAGGACCAGGTGGAAATCC GCGGAGGAGAGAAACAGAGAT
RT-PCR}/Q-RT-PCR β-actin GCTCGTCGTCGACAACGGCTC CAAACATGATCTGGGTCATCTTCT
PCR for cloning# HOPX CACCATGTCGGCGGAGACCGCGAGCGG GTCTGTGACGGATCTGACACTCTG
Abbreviations: Tm, annealing temperature.
†: Bisulfite sequencing PCR was done at 95°C for 3 min followed by 40 cycles at 95°C for 1 min, 72°C for 2 min, and final extension at 72°C for 10 min,in a 50 μl reaction volume containing 1 μl treated DNA, 5 μl 10×
PCR buffer, 0.2 μm ol/l MgCl2, 0.2 μmol/l each primer and 0.2 μl Platinum
W Taq DNA Polymerase.
{: Q-MSP was done at 95°C for 3 min followed by 45 cycles at 95°C for 20 sec, 60°C for 30 sec, and 72°C for 30 sec, in a 25 μl reaction volume containing 100 ng treated DNA, 300 nmol/l fluorescent probe, and 25 μl
iQTM supermix.
}: RT-PCR was done at 95°C for 3 min followed by 30 cycles at 95°C for 1 min, 60°C for 1 min, and final extension at 72°C for 1 min, and final extension at 72°C for 10 min, in a 50 μl reaction volume containing 1 μl
cDNA, 5 μl 10× PCR buffer, 0.2 μmol/l dNTP mixture, 1.5 mmol/l MgCl2, 0.2 μm ol/l each primer and 0.2μl Platinum
W Taq DNA Polymerase.
: Q-RT-PCR was done at 95°C for 2 min followed by 40 cycle at 95°C for 15 sec, 60°C for 30 sec, and 72°C for 30 sec, in a 25 μl reaction volume containing 100 ng treated DNA, 300 nmol/l each primer, and 25 μl
iQTMPCR Mix.
#: PCR was done at 94°C for 2 min followed by 35 cycles at 94°C for 15 sec, 64.8°C for 15 sec, 68°C for 30 sec, and final extension at 68°C for 7 min, in a 50 μl reaction volume containing 1 μl cDNA, 5 μl 10×


















Figure 1 (See legend on next page.)
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Figure 1 Analysis of HOPX-β methylation and expression in pancreatic cancer cell lines-1. (A) Schematic diagram of the 3 spliced
transcript variants and common transcript core in HOPX (middle panel) and of CpG islands (gray area) in the 50-flanking region of HOPX gene
(bottom panel). Vertical bars indicate the dinucleotides CpG. Arrows indicate the sequences for bisulfite sequencing analysis or Q-MSP,
respectively. F1, F2 and F3 represent forward primers for HOPX-α (331 bp) and HOPX-γ (456 bp), HOPX-β (376 bp), and HOPX-core (254 bp) in
RT-PCR or Q-RT-PCR; R, common reverse primer; P, probe for Q-MSP; TSS, transcription start site; ATG, translation start codon. (B) Expression level
of HOPX in PC cell lines was examined by RT-PCR (left panel) and Q-RT-PCR (HOPX-β and core/β-actin x 100, (right panel). (C) Expression level of
HOPX in PC cell lines was examined by WB (top panel) and IP/WB (bottom panel). Transfectants we performed had the V5 epitope and
polyhistidine region in the C-terminal peptide, and so, added approximately 5 kDa to original protein.
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plexes were detected using the 3,30-diamino-benzidine
tetrahydrochloride (DAB) substrate, as a chromogen for
30 seconds or 2 minutes.
Plasmid and transfection
A full length cDNA of HOPX was previously isolated
and subcloned into pcDNATM3.1D/V5-His-TOPO vec-
tor (pcDNATM3.1-HOPX) [8]. The vector with self-
ligation was used as a mock control. Plasmid vectors
were transfected into 2 pancreatic cancer cell lines (MIA
Paca2 and PANC-1) using Lipofectamine 2000 reagent
(Invitrogen). Stable clones with HOPX or mock were
established by G418 (GIBCO) selection (MIA Paca2,
800 μg/ml; PANC-1, 1200 μg/ml).
Proliferation assay
Cell proliferation and viability (2×103 cells/well) were
measured using the Premix WST-1 Cell Proliferation
Assay System (Takara Bio, CO., Tokyo, Japan) in 96-well
plates. Experiments were performed in triplicate.
Invasion assay
Cells were seeded at density of 1× 106 cells/well in the
24-well BD BioCoat Matrigel Invasion Chamber (BD
Biosciences Discovery Labware, Bedford, MA) filled with
500 μl DMEM (GIBCO). As a chemoattractant, 10% FBS
in 750 μl DMEM (GIBCO) was used for the assay. After
incubation for 22 hrs, the membrane of the upper cham-
ber was fixed and stained by Diff-Quick reagent
(Sysmex, Kobe, Japan). Invaded cells were counted in for
randomly selected sites per membrane.
Anchorage-independent colony formation assay
Anchorage-independent cell growth was analyzed by
plating 0.36% top agarose (BactoTM Ager, Becton
Dickison and Company, Franklin Lakes, NL) containing
1×105 cells on a surface of 0.72% bottom agarose in 6-
well plates. Two independent experiments were per-
formed and each experiment was done in triplicate.
Cell cycle assay
Cells (1× 106 cells/ml) were fixed in 75% ethanol, 5×105
cells stained with propidium iodide (Guava cell cyclereagent, Guava Technologies, Hayward, CA) and the cell
cycle assay was carried out using the Guava PCA
System. The experiment was performed in triplicate and
analyzed using CytoSoft 2.1.5 software (Guava
Technologies).
Statistical analysis
Fisher’s exact test, the chi-square test, Mann-Whitney’s
U test or Kruskal-Wallis rank test used for categorical
variables, and Student’s t-test was used for continuous
variables. Clinicopathological characteristics and follow
up data were analyzed in association with 5 year disease
specific survival (DSS). The follow up time was calcu-
lated from the date of surgery to death. DSS was calcu-
lated by Kaplan-Meier method, and survival differences
were assessed in the log-rank test. Variables suggested to
be prognostic factors on univariable analysis (P < 0.05)
were subjected to multivariable analysis using a Cox
proportional-hazards regression model. Data is expressed
as mean± standard deviation (SD), and P-value <0.05 was
considered to indicate statistical significance. All statistical
analyses were conducted with SAS software package (SAS
Institute, Cary, NC).
Results
Structure of HOPX promoter region
Genomic structure of HOPX gene is shown in Figure 1A.
HOPX has 3 unique transcript variants with 2 discrete
promote regions, and all of the 3 transcripts have the same
open reading frame. Among the 3 variants, only HOPX-β
harbours promoter CpG islands (promoter B) encom-
passed by the first exon and intron [8].
Expression level of HOPX transcripts (core and each
transcript-α, β, and γ) and protein in PC cell lines
We first examined expression of HOPX core transcripts,
in which PCR primers were shared for all the 3 tran-
scripts (Figure 1A). Among the 8 PC cell lines tested,
only KLM-1, PK-8, and PK-45 H cells express slight ex-
pression of HOPX core transcript, where HOPX core
transcript is consistent with HOPX-α/-γ transcripts. On
the other hand, HOPX-β was not detected at mRNA
level in any 8 PC cell lines (Figure 1B). WB analysis also
revealed that HOPX protein was hardly detected in any
Figure 2 (See legend on next page.)
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Figure 2 Analysis of HOPX-β methylation and expression in pancreatic cancer cell lines-2. (A) Representative bisulfite sequencing results in
5 PC cell lines and TE15. Arrowhead indicates dinucleotide CpG. (B) Cloned PCR products from PC cell lines. White and black circles denote
unmethylated and methylated CpG sites, respectively. X means seven nucleotide deletion; AGGCCGG. (C) mRNA expression by RT-PCR (top panel)
and Q-RT-PCR (bottom panel) after treatment with the demethylation agent, 5-aza-dC, in the presence or absence of TSA, a histone deacetylase
inhibitor. 1A and 5A, 1 and 5 μM 5-aza-dC; T, TSA.
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(Figure 1C), which could detect very weak but consistent
expression of HOPX protein in KLM-1, PK-8, and PK-
45 H at 10 kDa [7,9,14]. As HOPX transfectants and
positive control TE15 showed considerable expression
(Figure 1C), we concluded that HOPX expression
showed very little, if any, in PC cells.
Characteristics of promoter B methylation in PC cell lines
We initially examined the HOPX-β promoter methyla-
tion in all the 8 PC cell lines by bisulfite treatment fol-
lowed by direct sequencing, and promoter B of HOPX
gene was proved to be completely methylated in cytosine
residues of CpG islands in 7 PC cells except PANC-1
and MIA Paca2 (Figure 2A, B).
In order to demonstrate whether HOPX silencing of
PC cells is due to epigenetic abnormalities, demethylat-
ing agents such as 5-Aza-dC and/or trichostatin A were
added to PC cells, and reactivation of HOPX transcripts
was evaluated by RT-PCR and Q-RT-PCR (Figure 2C).
Differently from other GI cancers, reactivation was
recognized in small portions of PC cells to the small ex-
tent (Figure 2C). Reactivation by the most optimal
demethylating conditions was only found in PK-45 H
and PK-59, suggesting that reduction of HOPX gene
could be partially explained by epigenetic alterations of
HOPX promoter B. HOPX absent expression in MIA
Paca2 was also confirmed even after epigenetic reversion.
We could have therefore postulated homozygous dele-
tion to explain this absent expression. However, DNA
could be amplified for the promoter regions of HOPX-β,
and actual cloned sequence largely showed unmethyla-
tion in MIA Paca2 (Figure 2B). Other cancer cell lines
also showed very little expression of HOPX-β, so consti-
tutive transcription signal to activate HOPX-β expression
was defective in PC cell lines. However, this result does
not represent meaningless significance of HOPX methy-
lation, and we continued methylation analysis in primary
PC tissues.
Expression of HOPX transcripts and protein in PC tissues
and the corresponding normal pancreas tissues
We first examined the expression status of HOPX
transcripts for both the primary tumors and the
corresponding pancreas tissues in the 5 consecutive
advanced PC patients by both semi-quantitative RT-PCRand Q-RT-PCR. As a result, HOPX-β transcripts were
rather robustly over-expressed in the primary PC tissues
as compared to the corresponding normal tissues
(Figure 3A). WB also showed HOPX protein over-
expression in tumor tissues as compared to in the corre-
sponding normal tissues (Figure 3B).
In order to confirm predominant localization of HOPX
protein in primary PC, we then performed immunohisto-
chemistry (Figure 3C, D). Surprisingly, HOPX was
strongly immunostained almost exclusively for pancreatic
islet cells by short term exposure (30 seconds) of DAB.
Neither cancer cells nor normal pancreatic components
such as acinar and ductal cells showed staining of HOPX
(Figure 3D). On the other hand, islet cells in normal pan-
creas also showed considerable immunostaining of HOPX
(Figure 3D). These findings suggested that predominant
expression of HOPX transcripts and protein in primary
PC represents those of islet cells.
Instead of intense immunostaining of pancreas islet
cells, pancreatic duct and a portion of acinar cells were
also immunostained by intermediate exposure (2 min-
utes) of DAB (Figure 4A). The cellular localization of
HOPX existed mainly in cytoplasm. Under such condi-
tions, we investigated the IHC staining of HOPX for 11
cases with high methylation value and 9 cases with low
methylation value, respectively. In high methylation
value tissues, absent expression of HOPX was confirmed
despite frequent inclusion of heterogeneity. However, 9
samples with low methylation value exhibited relatively
strong HOPX expression, while only one sample showed
negative expression (Figure 4A). These results indicated
that expression of HOPX protein was associated with
promoter hypermethylation.
Using the same primers and probes in gastric cancer
study [8], we examined both 89 primary PC tissues and
84 corresponding non tumor tissues by Q-MSP analysis
(Figure 4B). The most optimal cut-off value was calcu-
lated for 1.5 from a receiver-operator characteristic
(ROC) analysis in order to maximize both sensitivity and
specificity of PC detection (Figure 4C), where sensitivity
was 83.2%, and specificity was 76.2%.
The overall methylation value detected in primary PC tis-
sue (14.50±16.53) was significantly higher than that in the
non tumoral tissues (3.64±12.02) (P<0.0001) (Figure 4B).
In addition, the methylation values within primary PC tis-
sues were significantly higher than those within non tumor
Figure 3 (See legend on next page.)
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Figure 3 HOPX expression status in PC. (A) Expression level of HOPX in PC was tested in RT-PCR (top panel) and Q-RT-PCR (bottom panel). T,
primary tumor; N, corresponding pancreatic tissue. (B) Expression level of HOPX in PC was examined by western blotting.
(C) Immunohistochemical staining for HOPX in primary tumor (top panel) and normal tissue (bottom panel), with hematoxylin eosin staining
(original magnification, X40). These immunohistochemical stainings were performed by short term exposure of DAB. (D) In this condition, islet
cells only stained (original magnification, X400). scale Bars, 100 μm.
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did not significantly differ in each stage (Figure 4D).
We further investigated whether the HOPX-β methy-
lation value was able to predict patient’s outcomes. Log-
rank plot analysis [18] showed that any cut-off value
could not represent prognostic stratification in PC
(Figure 4E). We preliminarily analyzed the correlation
between HOPX-β hypermethylation and the clinico-
pathological parameters, but none of any clinicopatholo-
gical variables was associated with methylation status of
HOPX-β (Additional file 2 Table S2).
HOPX stable transfectants caused suppression of
aggressive PC cell phenotypes
Two cell lines of pancreatic adenocarcinoma such as
PANC-1 and MIA Paca2 cells were transfected with
pcDNATM3.1-HOPX with V5-tagged and established
stable HOPX-expressing cell lines. In the HOPX stable
cell lines, exogenous mRNA expression level in cells
with the most abundant expression was comparable to
physiological expression level in human PC tissues.
HOPX protein was confirmed by 3D6 antibody and anti-
V5 antibody. Exogenously expressed tagged HOPX was
detected as approximately 15 kDa which is consistent
with mRNA levels (Figure 5A).
HOPX transfectants showed both less viability by
WST assay (Figure 5B) and remarkable reduction of col-
onies in soft agar (Figure 5C) as compared with mock
cells. Moreover, we found considerable suppression of
invasion activity in HOPX-expressing cells by Matrigel
invasion assay (Figure 5E). Cell cycle analysis further
revealed that HOPX increased fractions of both subG1
fraction and G0/G1, accompanied by decreased fraction
of both S and G2/M, indicating that both G1 arrest and
apoptotic sensitivity may be at least partially involved in
tumor suppressive traits of HOPX-expressing cell
(Figure 5D and Additional file 3 Table S3).
Discussion
We have recently identified HOPX as genes specifically
methylated in human cancers [7,8] after developing algo-
rithm utilizing pharmacological unmasking microarray
(PUM) [5,6]. Among the identified candidates of TSGs,
HOPX is of particular interest in terms of methylation
and functional involvement in tumor aggressiveness.
Other groups also recapitulated the similar finding thatHOPX promoter DNA is hypermethylated specifically in
endometrial cancer [15]. In this present study, we for
the first time added pancreatic cancer to the list of
organs in which HOPX is involved in carcinogenesis.
HOPX harbors 2 discrete promoter regions, promoter A
and promoter B. Promoter B has CpG islands, while pro-
moter A does not have them, and cancer-specific hyper-
methylation is recognized in the promoter B in primary
PC tissues as well as other GI cancers [7,8]. Such inde-
pendent regulation of the discrete promoter regions was
reported in other critical methylation genes such as
RASSF1 [19], and possession of the complex promoter
regions may indicate their functional importance in bio-
logical relevance. On the other hand, epigenetic reactiva-
tion of HOPX gene expression was much less than
expected in PC cell lines as compared to other GI cancer
cell lines. Allowing for actual expression in primary cancer
tissues, constitutive HOPX expression signal was derived
from carcinoma-stroma interaction in primary PC cells.
Pancreatic cancer is a ductal carcinoma, however it is
controversial which normal components (ductal cells, aci-
nar cells, or islet cells) of the pancreatic tissues are precur-
sor cells for PC [20,21]. Pour et al. proved that
transplantation of islets into the submandibular gland of
Syrian golden hamsters followed by treating with nitrosa-
mine N-nitrosobis-(2-oxopropyl)amin (BOP), a carcinogen
for PC led to the development of ductal pancreatic adeno-
carcinoma in this site, while PC did not occurred after
transplanting ductal and acinar cells into this gland [22].
Schmied et al. has also insisted that islet cells contribute
to pancreatic carcinogenesis in an animal model and dis-
ease exploration [23,24]. In mice with hamster islets
implanted in the splenic lobe of the mouse pancreases,
pancreatic ductal adenocarcinomas developed in the
implanted animals, but not in control mice, after BOP
treatment [25]. These findings strongly supported the hy-
pothesis that PC is generated from islet cell origin. In this
current study, we for the first time revealed that islet cells
expressed abundant HOPX protein in primary PC tissues
as well as the normal pancreas. It is intriguing hypothesis
that cancer cell with low expression of HOPX is derived
from islet cells which constitutively express abundant
HOPX, and that promoter DNA hypermethylation is
causative for gene silencing.
Clinical findings also supported hypothesis that the
islet cell is alternatively involved in PC carcinogenesis
Figure 4 (See legend on next page.)
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Figure 4 Immunohistochemistry and Quantitative methylation analysis in 89 samples. (A) Representative immunohistochemical staining
for HOPX in normal tissues and primary tumor with or without HOPX-β hypermethylation (original magnification, left X200, right X400). scale Bars,
100 μm. (B) Frequency of HOPX-β hypermethylation by Q-MSP. Dashed line indicates the optimal cut-off value (1.5). (C) ROC curve of HOPX-β
methylation for detection of PC. Area under the curve (AUC) represents the accuracy in discriminating normal from tumor in term of sensitivity
and specificity (P < 0.0001). (D) Methylation value of HOPX-β in JPS stage III, IVa and IVb. Data are expressed as mean± SD. (E) Identification of an
optimal cut-off value for the prognosis using the log rank prognostic analysis.
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cells was observed in primary PC tissues. Ten out of the
14 cancer specimens showed a significant loss of beta
cells (P < 0.005) and eight of them also showed a signifi-
cant increase of alpha cells (P < 0.005), all of them from
hyperglycemic patients. Most affected islets were found
within zone 1 (intratumoral) and zone 2 (peritumoral),
to a lesser extent in zone 3 (acini close to tumor) and
none in zone 4 (acini remote from tumor). The inci-
dence of 72% with alteration of islets in their material
correlates with the frequency of abnormal glucose levels
in human pancreatic cancer patients. In our study,
HOPX is remarkably increased in primary PC tissues,
and it was predominantly expressed in the islet cells.
These findings suggested that alteration of HOPX ex-
pression in the islet cells may explain the link of PC to
diabetes mellitus, and this mechanistic possibility should
be paid attention in the next future, as oncogenic role of
islet cells remains elusive during PC carcinogenesis.
HOPX actually suppressed tumor aggressiveness of PC
cells (PANC-1 and MIA Paca2). WST assay showed that
HOPX suppressed cell viability putatively representing
cell proliferation ability. In cell cycle analysis, HOPX
increased subG1 and G0/G1 phases, representing apop-
totic induction and inhibition of DNA synthesis, sug-
gesting that cell cycle abnormalities may be linked to
cell viability. More importantly, HOPX could inhibit
tumor-forming ability in soft agar, which is supposed to
represent metastatic trait of tumor cells [26]. Interest-
ingly, HOPX has been demonstrated to suppress tumori-
genesis in soft agar in ESCC and gastric cancer as well
as pancreatic cancer, hence anchorage independent
growth suppression is the common feature of HOPX ex-
pression in human cancers. Finally, HOPX also affects
Matrigel invasion less than other phenotypes in PC.
These findings may directly show gene silencing of
HOPX involved in PC aggressiveness.
Such tumor suppressive effects as shown in Figure 5
might include artifact effect, because expression level of
HOPX protein in transfectants may not correspond to
the physiological level of the originated normal cell, if
precursor cells of the PC were ductal or acinar cells. On
the other hand, HOPX expression level of the islet cells
reached similar level of the transfectants in our current
study. More importantly, the level of expression in thetransfectants of the current study was comparable with
those of normal mucosa of other tissues such as gastric
[8] and colorectal mucosa [27]. As compared to such
common solid tumors, PC exhibited uniquely dismal
prognosis, which is consistent with low expression of
HOPX in PC. As constitutive expression of HOPX in
human cancer cell lines including PC cell lines was in-
frequently found, RNA knockdown experiments was im-
possible to verify the endogenous role of HOPX in
human pancreatic cancer cells, however we previously
investigated RNA knockdown effects of HOPX by using
esophageal cancer cells, TE15 that is a rare control cell
which constitutively expressed HOPX [7,8], and tumor
suppressive role was confirmed. DNA hypermethylation
of HOPX with gene silencing is therefore likely to affect
PC phenotypes as in other cancers. On the other hand,
there were some limitations of the conclusions that can
be made based on our functional assay. In MIA Paca2
cells, HOPX was unlikely to be inactivated by methyla-
tion, and transfected HOPX protein of PANC-1 cells
was expressed relatively weakly. Hence, our conclusion
on tumor suppressive role of HOPX on PC was based
largely on epigenetic characteristics in primary PC, and
results of PC cell lines remained supplementary. We
would like to know more specific and definitive conclu-
sions as to these concerns in the near future.
HOPX affects gene transcription through recruitment
of HAT and/or HDAC activity for specific transcriptional
factors [28-30]. Yeast two hybrid identified enhance of
polycomb-1 (Epc-1), a critical component of NuA4 HAT
complex, as a binding partner of HOPX, and augments
transcription of heart differentiation genes. Interestingly,
Epc1 was demonstrated to be associated with EZH2
which is required for cellular proliferation, E2F6-PcG
complex (E2F6-EPC1) that interacts with EZH2 and may
regulate genes required for cell cycle progression [31,32].
Thus, HOPX may therefore affect critical process of
chromatin conformation change to affect expression of
onco-molecules.
Collectively, we found that HOPX methylation is a
very frequent and cancer specific event in PC develop-
ment. We further elucidated that HOPX is a putative
tumor suppressor gene critical for tumor aggressiveness
in PC. We are also interested in alternate aspects of
HOPX in terms of a role in islet cells. We must confirm
Figure 5 (See legend on next page.)
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Figure 5 Functional analysis of HOPX in PC cells. (A) HOPX expression level in HOPX expressing stable cell lines was determined by mRNA
expression (lower panel) and protein expression (upper panel). HOPX protein was detected by WB with HOPX antibody (3D6) and the flag V5
antibody. β-actin was shown as a loading control. (B) Proliferation assay was performed for 5 days. Data are shown as absorbance at 450 nm.
error bars, SD. (C) Anchorage-independent colony formation assay was performed. After 3 weeks of cell culture, colonies were counted and
photographed at 40× magnification under a microscope. Colonies were also visualized by ethidium bromide staining. error bars, SD. (D) Image of
cell cycle assay. Thick black bars, subG1 phase. (E) Matrigel invasion assay. After fixation and staining, invading cells were photographed and
counted at 100x magnification. error bars, SD.
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phenotype alteration by HOPX abnormalities in PC in
future study.
Conclusions
Defective expression of HOPX which is consistent with
CpG islands promoter DNA hypermethylation may explain
aggressive phenotype of pancreatic cancer, and intense ex-
pression of HOPX in the Langerhans islet cells may in turn
uniquely contribute to pancreatic carcinogenesis.
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